The IMPACT Clinical Trials Network is excited to collaborate with Dr Giovanna Lucchini at Great Ormond Street Hospital (GOSH) on a study of COVID19 infection in allogenic stem cell recipients
This study will be taking place at adult and paediatric stem cell transplant centres throughout the UK. There are currently nine centres open, with more due to open in the coming weeks. With sites now up and running, we are excited to announce we enrolled our first patient into the study last week at Bristol Haematology and Oncology Centre.
The study addresses an unmet need as there is currently no data available regarding the risk of severe COVID19 disease in patients post stem cell transplantation. Due to the immunological challenges that this patient population face, it is unclear how COVID19 may affect their clinical progression.
Therefore, this study is looking at patients (both adult and paediatric) post-transplant with severe COVID19 infection, collecting blood samples, as well as clinical data at 30 and 100 days. By looking at this clinical and biological data, we will investigate the inflammatory and immune response of these patients, and understand how this affects patient outcomes. Our aim is that this vital information will help us provide a scientific basis for using targeted therapies in the treatment of blood cancer patients with COVID-19 infection.
“This non-interventional study will recruit adults and children from UK IMPACT centres and may help us better understand the mechanisms of lung dysfunction in this patient group, and the factors that are associated with an adverse outcome”Professor David Marks, IMPACT Medical Director
post by Rebecca Collings, IMPACT Senior Trial Coordinator